Genprex

NASDAQ : GNPX

MANAGEMENT TEAM:

Rodney Varner JD, Founder & Chief Executive Officer
Julien Pham MD, MPH, President & Chief Operating Officer
Ryan Confer MS, Chief Financial Officer

BOARD OF DIRECTORS:

Rodney Varner JD, Chairman
Bob Pearson, Experience Global Pharma Communications
David Friedman JD, Experience Finance & Compliance
James Rothman, PhD, Strategic Advisor to the Board

SCIENTIFIC ADVISORY BOARD:

Jack Roth, MD, Scientific Founder & Chairman
George Simon, MD
Pasi Antero Janne, MD, PhD
Tony S.K. Mok, MD

INTELLECTUAL PROPERTY:

30+ Patents Issued, 2 Pending
MD Anderson Cancer Center, NIH NCI

AN UNMET MEDICAL NEED: LUNG CANCER

- Second-most common cancer
- Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers
- 225,000 new cases per year in the U.S; 1.8 million cases worldwide
- Five-year survival rate for Stage IV NSCLC approx. 1%

ONCOPREX™ COMPETITIVE ADVANTAGE:

- Clinically proven to selectively kill cancer cells while sparing normal cells
- 10- to 25-fold uptake by tumor cells over normal cells
- Harness the body's natural tumor-suppressing mechanisms to detect and destroy cancer cells
- Provide therapeutic benefit to patients who have developed resistance to EGFR inhibitors
- Combination with approved products could unlock NSCLC market for patients that cannot benefit from existing therapies
- Significant cancer-killing synergy when combined with a variety of kinase inhibitors including those targeting EGFR and AKT, and with checkpoint inhibitors

KEY RESEARCH COLLABORATIONS:

UT MD Anderson Cancer Center
UT Health Science Center San Antonio

CONTACT INFORMATION:

1601 Trinity Street, Bldg. B, Suite #3.322
Austin, Texas 78712
Tel: 877-774-GNPX (4679)
Email: info@genprex.com
Web: www.genprex.com

COMPANY & PLATFORM OVERVIEW

Genprex Inc. (NASDAQ : GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

AN UNMET MEDICAL NEED: LUNG CANCER

Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards.

R&D PIPELINE AND PATH TO APPROVAL



LEAD CANDIDATE ONCOPREX

Genprex's initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC.

TARGET MARKET OPPORTUNITY

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.